• Product NameDarapladib (SB-480848)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityDarapladib (SB-480848) is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM. Phase 3.
• Target NamePhospholipase inhibitor
• CAS No. 356057-34-6
• Calculated MW 666.77
• Formulation C36H38F4N4O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Respiratory system/ Cardiovascular system/ Metabolism
  SMILES:CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1
  Pathways:Metabolism
  Receptor:Lp-PLA2
  Boling pt:
  Melting pt:
  Solubility:DMSO:100 mg/mL warmed (149.97 mM)Ethanol:100 mg/mL (149.97 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Blackie JA, et al. Bioorg Med Chem Lett. 2003, 13(6), 1067-1070.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting